UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

  

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

June 9, 2021

  

 

 

LIPOCINE INC. 

(Exact name of registrant as specified in its charter)

 

Commission File No. 001-36357 

 

Delaware   99-0370688
(State or other jurisdiction of incorporation)   (IRS Employer Identification Number)

 

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (801) 994-7383

 

Former name or former address, if changed since last report: Not Applicable

______________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Market LLC

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

  

Item 5.07Submission of Matters to a Vote of Security Holders

 

On June 9, 2021, the Company held its annual general meeting of shareholders, at which time the following items were voted upon:

 

(1)Election of Directors. The Company’s shareholders elected for a one-year term four persons nominated for election as directors. The following table sets forth the vote of the shareholders at the meeting with respect to the election of directors:

 

Nominee  For  Withheld 

Broker

Non-Vote

Dr. Mahesh V. Patel  18,204,805  3,711,152  29,005,675
Jeffrey A. Fink  14,717,241  7,198,716  29,005,675
John W. Higuchi  17,993,157  3,922,800  29,005,675
Dr. Richard Dana Ono  14,566,235  7,349,722  29,005,675

 

There were no abstentions with respect to the election of directors.

 

(2)Ratification of Appointment of Independent Registered Public Accounting Firm. The Company’s shareholders voted upon and ratified the appointment of Tanner LLC as the Company’s independent registered public accountants for the fiscal year ending December 31, 2021. The following table sets forth the vote of the shareholders at the meeting with respect to the appointment of Tanner LLC:

 

For   Against   Abstain
48,767,641   1,082,474   1,071,517

 

There were no broker non-votes in the ratification of appointment of Tanner LLC as the Company’s independent registered public accountants for the fiscal year ending December 31, 2021.

 

(3)Advisory Vote on Executive Compensation. The Company’s shareholders voted upon and adopted a non-binding resolution approving the compensation of the Company’s named executive officers. The following table sets forth the vote of the shareholders at the meeting with respect to the adoption of this resolution on named executive officer compensation:

 

For   Against   Abstain Broker Non-Vote
14,255,085   5,927,031   1,733,841 29,005,675

 

(4)Amendment to the Amended and Restated Certificate of Incorporation of the Company to Increase the Number of Authorized Shares of Common Stock. The Company’s shareholders voted against the proposal to amend the Amended and Restated Certificate of Incorporation of the Company to increase the number of authorized shares of common stock. The following table sets forth the vote of the shareholders at the meeting with respect to this proposal:

 

For   Against   Abstain
31,917,814   17,100,025   1,903,793

  

(5)Amendment and Restatement of the Fourth Amended and Restated 2014 Stock and Incentive Plan. The Company’s shareholders voted against the amendment and restatement of the Fourth Amended and Restated 2014 Stock and Incentive Plan. The following table sets forth the vote of the shareholders at the meeting with respect to the amendment and restatement of the Fourth Amended and Restated 2014 Stock and Incentive Plan:

 

For   Against   Abstain Broker Non-Vote
8,214,701   12,149,020   1,522,236 29,005,675

 

  

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      LIPOCINE INC.
         
         
Date: June 9, 2021   By: /s/ Mahesh V. Patel
        Mahesh V. Patel
        President and Chief Executive Officer